CARTITUDE-1 evaluated cilta-cel in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients with historically poor outcomes. At 60.3 months follow-up, 33% remained progression-free ≥5 years post-infusion, showing significant biomarker correlations and durable responses. Median overall survival (OS) was 60.6 months, supporting cilta-cel's potential curative role in RRMM.

Key Points:
- Research Problem/Question: Assess long-term efficacy of cilta-cel in RRMM.
- Methodology: Single infusion in CARTITUDE-1, with correlative analyses.
- Key Findings: 33% remained progression-free ≥5 years; biomarker correlations identified predictors.
- Significance/Impact: Demonstrates potential curative effect in RRMM.

Conclusion:
The long-term follow-up of CARTITUDE-1 highlights cilta-cel's remarkable efficacy in achieving prolonged progression-free survival and significant OS benefits in heavily pretreated RRMM patients.

Authors:
Peter Voorhees, Tom Martin, Yi Lin, Adam Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Hui Li, Rocio Montes de Oca, Huabin Sun, Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath.

Clinical Trial Registration Number:NCT03548207, NCT05201781
DOI:10.1200/JCO.2025.43.16_suppl.7507
Abstract #7507